# Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

> **NCT05707910** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **West China Hospital** · enrollment: 6 (actual)

## Conditions studied

- Malignant Tumor

## Interventions

- **BIOLOGICAL:** EBV immunological agent

## Key facts

- **NCT ID:** NCT05707910
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-08
- **Primary completion:** 2024-04-24
- **Final completion:** 2027-12-31
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05707910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05707910, "Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05707910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*